Fernand Labrie

Publications

Page 6 of 26, showing 50 records out of 1263 total, starting on record 251, ending on 300

Publication Category Year
4700. Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, J.L., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I., Labrie, C., Lavoie, L., Berger, L., Gilbert, L, Balser, J. (2009) Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women, Menopause, 16: 923-931. All publications 2009
4701. Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, J.L., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I., Labrie, C., Lavoie, L., Berger, L., Gilbert, L, Martel, C., Balser, J. (2009) Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy, Menopause, 16: 907-922. All publications 2009
4702. Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, J.L., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I., Labrie, C., Lavoie, L., Berger, L., Gilbert, L, Martel, C., Balser, J. (2009) Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration, Menopause, 16: 897-906. All publications 2009
576. Labrie, F., Bélanger, A., Bélanger, P., Bérubé, R., Martel, C., Cusan, L., Gomez, J., Candas, B., Castiel, I., Chaussade, V., Deloche, C., Leclaire, J. (2006) Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol, 99: 182-188. All publications 2006
559. Labrie, F., Bélanger, A., Bélanger, P., Bérubé, R., Martel, C., Cusan, L., Gomez, J., Candas, B., Chaussade, V., Castiel, I., Deloche, C., Leclaire, J. (2007) Metabolism of DHEA in postmenopausal women following percutaneous administration., 103: 178-88. All publications 2007
577. Labrie, F., Bélanger, A., Bélanger, P., Bérubé, R., Martel, C., Cusan, L., Gomez, J.L., Candas, B., Chaussade, V., Castiel, I., Deloche, C., Leclaire, J. (2006) Metabolism of DHEA in postmenopausal women following percutaneous administration. J Steroid Biochem Mol Biol, 103: 178-88. All publications 2006
622. Labrie, F., Bélanger, A., Cusan, L., Candas, B. (1997) Physiological changes in DHEA are not reflected by the serum levels of active androgens and estrogens but of their metabolites: intracrinology. J. Clin. Endocrinol. Metab., 82: 2403-2409. All publications 1997
623. Labrie, F., Bélanger, A., Cusan, L., Gomez, J.L., Candas, B. (1997) Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J. Clin. Endocrinol. Metab., 82: 2396-2402. All publications 1997
97. Labrie, F., Bélanger, A., Cusan, L., Labrie, C., Simard, J., Luu-The, V., Gomez, J.L., Diamond, P., Candas, B. (1996) History of LHRH agonist and combination therapy in prostate cancer. Endocrine-Related Cancer, 3: 243-278. All publications 1996
139. Labrie, F., Bélanger, A., Dupont, A., Luu-The, V., Simard, J., Labrie, C. (1993) Science behind total androgen blockade: from gene to combination therapy. Clin. Invest. Med., 16: 475-492. All publications 1993
172. Labrie, F., Bélanger, A., Dupont, A., Pelletier, G., Luu-The, V., Simard, J., Cusan, L., Labrie, C., Lachance, Y., Poulin, R., Dupont, E., Zhao, H.F., Martel, C. (1990) Synthèse périphérique des androgènes chez l'homme. Génétique moléculaire du système et sa prise en compte dans le traitement du cancer de la prostate. Médecine/Sciences, 6: 261-267. All publications 1990
560. Labrie, F., Bélanger, A., Labrie, C., Candas, B., Cusan, L., Gomez, J.L. (2007) Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women. J Steroid Biochem Mol Biol, 107: 57-69. All publications 2007
735. Labrie, F., Bélanger, A., Luu-The, V. (2007) Biosynthèse et sécrétion des hormones stéroïdiennes, in: Chanson, P., ed. Traité d'Endocrinologie, Paris: Flammarion Médecine-Sciences, pp 13-19. All publications 2007
19. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J., Candas, B. (2005) Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocrine Reviews, 26: 361-379. All publications 2005
791. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Lin, S.-X. (2000) DHEA, the precursor of androgens and estrogens in peripheral tissues in the human: intracrinology, in: Kalimi, M. et Regelson, W., eds: (DHEA): Biochemical Physiological and Clinical Aspects, pp 191-213. All publications 2000
399. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Labrie, C. (2001) DHEA replacement therapy as source of androgens and estrogens at menopause, in: Genazani, A.R., Petraglia, F. et Artini, P.G., eds: Advances in Gynecological Endocrinology, London, UK, Parthenon Publishing, pp 249-258. All publications 2001
395. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Labrie, C. (2002) DHEA replacement therapy as a source of androgens and estrogens at menopause, in: Genazzani, A.R., Petraglia, F. et Artini, P.G., eds: Advances in Gynecological Endocrinology, Florence, Italy, Parthenon Publishing, pp 249-258. All publications 2002
140. Labrie, F., Bélanger, A., Simard, J., Labrie, C., Dupont, A. (1993) Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first line therapy. Cancer, 71: 1059-1067. All publications 1993
634. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C. (1995) DHEA and peripheral androgen and estrogen formation: intracrinology. Ann. N.Y. Acad. Sci., 774: 16-28. All publications 1995
111. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C. (1995) Intracrinologie: autonomie et liberté des tissus périphériques. Ann. Endocrinol. (Paris), 56: 23-29. All publications 1995
98. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Cusan, L., Gomez, J., Diamond, P., Candas, B. (1996) Sources d'androgènes chez l'homme et traitement hormonal du cancer de la prostate (Chapter 16), in: Belaisch, J., Drodowsky, M.A. et Vermeulen, A., eds: Progrès en Andrologie: Endocrinologie Masculine, Doin, pp 215-229. All publications 1996
61. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Lin, S.-X., Candas, B., Cusan, L. (1999) Impact de l'intracrinologie dans la thérapeutique et la prévention des cancers du sein et de la prostate et de la ménopause, in: Guérité, N. et Leclère, J., eds: Mises au point cliniques d'endocrinologie, nutrition et métabolisme 1999, Paris, France, Les Éditions de Médecine Pratique, pp 169-204. All publications 1999
62. Labrie, F., Candas, B. (1999) Bicalutamide versus Flutamide in combination therapy [Letter to the Editor re: Schellhammer et al. 50: 330-336, 1997]. Urology, 53: 662-663. All publications 1999
63. Labrie, F., Candas, B. (1999) The Quebec study shows a 69% decrease in prostate cancer death [Authors' Response to comment of Alexander and Prescott on Prostate 38 (2): 83-91, 1999]. Prostate, 40: 137. All publications 1999
64. Labrie, F., Candas, B. (1999) Various statistical analyses indicate a marked reduction of prostate cancer death in the Quebec trial [Authors' Response to comment of Boer and Schroder on Prostate 38 (2): 83-91, 1999]. Prostate, 40: 132-134. All publications 1999
49. Labrie, F., Candas, B. (2000) Androgen blockade in prostate cancer [Letter-to-the-Editor]. Lancet, 356: 341-342. All publications 2000
3625. Labrie, F., Candas, B. (2002) Letter to the Editor. Re: Does PSA reduce prostate cancer mortality?-Interpreting the Quebec Prostate Cancer Study. CMAJ, 167: 340. All publications 2002
3578. Labrie, F., Candas, B. (2004) Author Response: The Quebec Screening Study Shows a 62% Decrease in Prostate Cancer Death. The Prostate, 61: 373-374. All publications 2004
39. Labrie, F., Candas, B., Cusan, L., Gomez, J.L. (2001) The Laval University screening trial results (Chapter 17), in: Thompson, I.M., Resnick, M.I. et Klein, E.A., eds: Current Clinical Urology, Prostate Cancer Screening, Totowa, NJ, Humana Press Inc., pp 255-279. All publications 2001
25. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Bélanger, A., Brousseau, G., Lévesque, J. (2004) Screening decreases prostate cancer mortality: 11-year follow-up on the 1988 Quebec prospective randomized controlled trial. The Prostate, 59: 311-318. All publications 2004
82. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Diamond, P., Lemay, M. (1997) Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen [Letter to the Editor: Reply to Brown and Feuer re 47: 212-7, 1996]. Urology, 49: 306-307. All publications 1997
100. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M. (1996) Diagnosis of advanced or non-curable prostate cancer can be practically eliminated by prostate-specific antigen. Urology, 47: 212-217. All publications 1996
3643. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Lévesque, J., Chevrette, E., Brousseau, G. (2001) Prostate Cancer Screening: The Only Way to Early Treatment and a Major Impact on Survival. Proceeding of the VIIth International Congress of Andrology, 461-468. All publications 2001
26. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Lévesque, J., Chevrette, E., Brousseau, G. (2004) Prostate Cancer Screening and Early Treatment: The Only Possibility for a Major Impact on Survival in Prostate Cancer, in: Labrie, F. et Koutsilieris, M., eds: Prostate Cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 67-78. All publications 2004
65. Labrie, F., Candas, B., Dupont, A., Cusan, L., Gomez, J.L., Suburu, R.E., Diamond, P., Lévesque, J., Bélanger, A. (1999) Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate, 38: 83-91. All publications 1999
35. Labrie, F., Candas, B., Gomez, L.J., Cusan, L. (2002) Can combined androgen blockade provide long term control or possible cure of localized prostate cancer? Urology, 60: 115-119. All publications 2002
386. Labrie, F., Champagne, P., Labrie, C., Roy, J., Laverdiere, J., Provencher, L., Potvin, M., Drolet, Y., Pollak, M., Panasci, L., L'Espérance, B., Dufresne, J., Latreille, J., Robert, E., Samson, B., Jolivet, J., Yelle, L., Cusan, L., Diamond, P., Candas, B. (2004) Activity and safety of the orally active precursor of EM-652 (Acolbifene) in Tamoxifen-resistant breast cancer. J Clin Oncol, 22: 864-871. All publications 2004
112. Labrie, F., Crawford, D.; (1995) Anti-androgens in treatment of prostate cancer. Lancet, 346: 1030-1031. All publications 1995
66. Labrie, F., Cusan, J., Gomez, J., Levesque, J., Candas, B. (1999) Screening and treatment of localized prostate cancer decreases mortality: first analysis of the first prospective and randomized study on prostate cancer screening. Society of the Study of the Aging Male, 2: 33-43. All publications 1999
101. Labrie, F., Cusan, L., Dupont, A., Gomez, J.-L., Simard, J., Luu-The, V., Pelletier, G., Labrie, C., Bélanger, A. (1996) Androgen receptor antagonists (Chapter 28), in: Adashi, E.Y., Rock, J.A. et Rosenwaks, Z., eds: Reproductive Endocrinology, Surgery and Technology, Philadelphia, Lippincott-Raven Publishers, pp 559-583. All publications 1996
27. Labrie, F., Cusan, L., Gomez, J., Luu-The, V., Candas, B., Bélanger, A., Labrie, C. (2004) Major impact of hormonal therapy in localized prostate cancer - death can already be an exception. JSBMB, 92: 327-344. All publications 2004
4690. Labrie, F., Cusan, L., Gomez, J.L., Côté, I., Bérubé, R., Bélanger, P., Martel, C., Labrie, C. (2008) Corrigendum to: Effect of Intravaginal DHEA on Serum DHEA and Eleven of its Metabolites in Postmenopausal Women. J Steroid Biochem Mol Biol, 112: 169 All publications 2008
1087. Labrie, F., Cusan, L., Gomez, J.L., Côté, I., Bérubé, R., Bélanger, P., Martel, C., Labrie, C. (2008) Effect of Intravaginal DHEA on Serum DHEA and Eleven of its Metabolites in Postmenopausal Women. J Steroid Biochem Mol Biol, 111: 178-194 All publications 2008
353. Labrie, F., Cusan, L., Gomez, J.L., Côté, I., Bérubé, R., Bélanger, P., Martel, C., Labrie, C. (2009) Effect of One-Week Treatment with Vaginal Estrogen Preparations on Serum Estrogen Levels in Postmenopausal Women. Menopause, 16: 30-36. All publications 2009
31. Labrie, F., Cusan, L., Gomez, J.L., Candas, B., Bélanger, A., Luu-The, V., Simard, J. (2003) De la biologie à la clinique: le décès dû au cancer de la prostate peut-il maintenant être une exception? Médecine/Sciences, 19: 910-19. All publications 2003
83. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Bélanger, A., Candas, B. (1997) Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer. Mol. Urol., 1: 253-261. All publications 1997
3756. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Bélanger, A., Candas, B. (1997). Combination therapy in localized prostate cancer (Chapter 4), in: Schrèoder, F.H., ed. Recent advances in prostate cancer and BPH: the Proceedings of the IV Congress on Progress and Controversies on Oncological Urology (PACIOu IV), held in Rotterdam, the Netherlands, April 1996, pp 31-43. All publications 1997
113. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Candas, B. (1995) Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality. J. Clin. Endocrinol. Metab., 80: 2002-2013. All publications 1995
114. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Candas, B. (1995) Screening und Re-Screening des Prostatakarzinoms: Die Quebec-Studie, in Faul, P. et Altwein, J.E., eds: Screening des Prostatakarzinoms, Berlin, Springer-Verlag, pp 339-352. All publications 1995
84. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Bélanger, A., Candas, B. (1997) Neoadjuvant hormonal therapy: the Canadian experience. Urology, 49: 56-64. All publications 1997
<< previous | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 next >>

Biography  |  Publications  |  Scientific Conferences  |  Selected Slide Presentations  |  Awards